Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06703021 · ClinicalTrials.gov registry record · Phase 2

A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity

A Phase 2 study of Obesity and Overweight, sponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics.

Active
Registry status
Phase 2
Development phase
82
Enrollment target
10
Study locations

NCT06703021: Active Phase 2 study of Obesity and Overweight, sponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics.

NCT06703021 is a Phase 2 study of Obesity and Overweight that is active but no longer recruiting, run by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics. The registered enrollment target is 82 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (90% lower). The trial reports 10 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06703021, a Phase 2 study of Obesity and Overweight, is active but no longer recruiting, sponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
82 participants
Enrollment target
10
Study locations

Study Summary

Phase 2 clinical study will evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of various aleniglipron (GSBR-1290) dose regimens compared with placebo in participants living with obesity or overweight with ≥ 1 weight-related comorbidity, in addition to diet and exercise, over a 44-week period.

Conditions Studied

Obesity Overweight Chronic Weight Management

Interventions

  • DRUG aleniglipron or placebo

Study Locations (10)

California

  • ACCESS II Research Site - Glendale
  • ACCESS II Research Site - Montclair

Texas

  • ACCESS II Research Site - Dallas
  • ACCESS II Research Site - San Antonio

Indiana

  • ACCESS II Research Site - Valparaiso

Iowa

  • ACCESS II Research Site - West Des Moines

Oregon

  • ACCESS II Research Site - Medford

Rhode Island

  • ACCESS II Research Site - East Greenwich

South Carolina

  • ACCESS II Research Site - North Charleston

Utah

  • ACCESS II Research Site - West Jordan

Trial Details

FieldValue
Enrollment Target 82 participants
Start Date 2024-12-20
Est. Completion 2025-12
Phase Phase 2
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

8 total trials

What the registry record for NCT06703021 still lists

NCT06703021 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 82 participants, a relatively small participant target, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (90% lower).

The record links to 3 conditions, with Obesity appearing as the primary indexed condition, and to 1 intervention - of which aleniglipron or placebo is the first listed.

NCT06703021 lists 10 locations in 8 states (California, Texas, Indiana).

Frequently Asked Questions

What is clinical trial NCT06703021 about?

NCT06703021 is a clinical study titled "A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity". Phase 2 clinical study will evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of various aleniglipron (GSBR-1290) dose regimens compared with placebo in participants living with obesity or overweight with ≥ 1 weight-related comorbidity, in addition to diet and exercise, over a 4...

What is the current status of trial NCT06703021?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 82 participants. The study started on 2024-12-20. Estimated completion is 2025-12.

What conditions does trial NCT06703021 study?

This clinical trial studies the following conditions: Obesity, Overweight, Chronic Weight Management.

What interventions are being tested in trial NCT06703021?

The interventions under investigation include: aleniglipron or placebo (DRUG).

Who is sponsoring clinical trial NCT06703021?

This trial is sponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06703021 being conducted?

This trial has 10 study locations across California, Indiana, Iowa, Oregon, Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06703021's enrollment target sits among peer trials

82 540th of 1053 higher than 512 of 1,053 other Obesity trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03319901 · 82 participants · Phase 1

    Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL

  • NCT03493425 · 82 participants · Phase 2

    Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery

  • NCT04105270 · 82 participants · Phase 2

    RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial

  • NCT04428658 · 82 participants · NA

    Randomized Trial of Supplemental Synchronous and Asynchronous Telehealth to Improve Glycemic Control for Pediatric Patients With Type 1 Diabetes

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT06703021, the US trial registry maintained by the National Library of Medicine. NCT06703021 (small enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.